Skip to content
DraconiticResearch
Search Sources API
178,033 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report

  • Yuanmei Dong1
  • Li Zhang2
  • Lan Zhao2
  • Yanyun Zhu1
  1. 1Department of Oncology, Chinese PLA General Hospital, The Fifth Medical Center
  2. 2Department of Oncology, Chinese PLA General Hospital, The First Medical Center
Open at sourceDOICite

Abstract

Introduction: Trastuzumab deruxtecan (T-DXd) has been approved for the second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer, revolutionizing the treatment landscape for this clinical scenario.

Case Presentation: Given the lack of real-world evidence, here we reported a patient with HER2-positive, metastatic gastroesophageal junction adenocarcinoma treated with T-DXd in the second-line setting. The patient, a 63-year-old male, previously received first-line treatment with trastuzumab plus oxaliplatin, capecitabine and sintilimab but disease progression occurred at 4.5 months. He subsequently received T-DXd-based therapy for a total of 22 treatment cycles and achieved a progression-free survival (PFS) of 23 months, with improved performance status and no T-DXd treatment dose reduction during treatment.

Conclusion: This case firstly supplements the real-world data of T-DXd for patients with HER2-positive advanced gastric cancer in the second-line setting. These data indicate the PFS benefit with second-line T-DXd-based treatment even after rapid progression on trastuzumab-based therapy and the safety of full-dose T-DXd during long-course treatment.

Related

  1. Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score ≥ 5%: results from the RATIONALE-305 trial
    Markus Moehler, Marcia Cruz Correa, Do Youn Oh +8
    Quality of Life ResearchPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMCEurope PMC
  2. Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report
    Myrtille Thomas, Mojgan Devouassoux-Shisheboran, Jonathan Lopez +5
    Gynecologic Oncology ReportsPeer-reviewedCC BYFull textGeneral biologyEpidemiology & public healthHAL
  3. Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1+
    Angelika Wolfrum, Julia Ladurner, Burghard Abendstein
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  4. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma
    y. chen, C. Haffner, B. Chellakkan Selvanesan +24
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  5. Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis
    J. Fan, A. Stenmark Tullberg, A. W. Kurian +3
    medRxivPreprintCC BY-NC-NDFull textOncologymedRxiv

Cite

BibTeXRIS
BibTeX
@article{dong2026progressionfree,
  title = {{Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report}},
  author = {Yuanmei Dong and Li Zhang and Lan Zhao and Yanyun Zhu},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = nov,
  doi = {10.3389/fphar.2026.1913044},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1913044/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report
AU  - Yuanmei Dong
AU  - Li Zhang
AU  - Lan Zhao
AU  - Yanyun Zhu
PY  - 2026
DA  - 2026/11/04
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1913044
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1913044/full
AB  - Introduction: Trastuzumab deruxtecan (T-DXd) has been approved for the second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer, revolutionizing the treatment landscape for this clinical scenario.  Case Presentation: Given the lack of real-world evidence, here we reported a patient with HER2-positive, metastatic gastroesophageal junction adenocarcinoma treated with T-DXd in the second-line setting. The patient, a 63-year-old male, previously received first-line treatment with trastuzumab plus oxaliplatin, capecitabine and sintilimab but disease progression occurred at 4.5 months. He subsequently received T-DXd-based therapy for a total of 22 treatment cycles and achieved a progression-free survival (PFS) of 23 months, with improved performance status and no T-DXd treatment dose reduction during treatment.  Conclusion: This case firstly supplements the real-world data of T-DXd for patients with HER2-positive advanced gastric cancer in the second-line setting. These data indicate the PFS benefit with second-line T-DXd-based treatment even after rapid progression on trastuzumab-based therapy and the safety of full-dose T-DXd during long-course treatment.
SN  - 1663-9812
ER  -